Sage Therapeutics Inc (SAGE)
12.89
-0.44
(-3.30%)
USD |
NASDAQ |
Apr 22, 16:00
12.90
+0.01
(+0.08%)
After-Hours: 20:00
Sage Therapeutics Enterprise Value: 21.59M for April 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 21.59M |
| April 19, 2024 | 48.04M |
| April 18, 2024 | 30.31M |
| April 17, 2024 | 2.357M |
| April 16, 2024 | 186.28M |
| April 15, 2024 | 167.65M |
| April 12, 2024 | 174.86M |
| April 11, 2024 | 242.78M |
| April 10, 2024 | 235.57M |
| April 09, 2024 | 239.78M |
| April 08, 2024 | 244.59M |
| April 05, 2024 | 233.77M |
| April 04, 2024 | 243.39M |
| April 03, 2024 | 277.65M |
| April 02, 2024 | 283.66M |
| April 01, 2024 | 322.73M |
| March 28, 2024 | 373.22M |
| March 27, 2024 | 391.25M |
| March 26, 2024 | 366.00M |
| March 25, 2024 | 370.21M |
| March 22, 2024 | 402.07M |
| March 21, 2024 | 447.15M |
| March 20, 2024 | 429.72M |
| March 19, 2024 | 405.67M |
| March 18, 2024 | 411.08M |
| Date | Value |
|---|---|
| March 15, 2024 | 447.15M |
| March 14, 2024 | 437.53M |
| March 13, 2024 | 485.62M |
| March 12, 2024 | 469.99M |
| March 11, 2024 | 519.88M |
| March 08, 2024 | 574.57M |
| March 07, 2024 | 531.30M |
| March 06, 2024 | 516.87M |
| March 05, 2024 | 522.88M |
| March 04, 2024 | 555.34M |
| March 01, 2024 | 560.75M |
| February 29, 2024 | 537.91M |
| February 28, 2024 | 602.22M |
| February 27, 2024 | 611.84M |
| February 26, 2024 | 607.03M |
| February 23, 2024 | 569.76M |
| February 22, 2024 | 584.19M |
| February 21, 2024 | 581.18M |
| February 20, 2024 | 579.38M |
| February 16, 2024 | 645.50M |
| February 15, 2024 | 774.13M |
| February 14, 2024 | 794.56M |
| February 13, 2024 | 630.47M |
| February 12, 2024 | 679.16M |
| February 09, 2024 | 670.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
0.2581M
Minimum
May 09 2022
8.541B
Maximum
Jul 12 2019
2.007B
Average
1.187B
Median
Mar 11 2020
Enterprise Value Benchmarks
| Biogen Inc | 34.12B |
| Perspective Therapeutics Inc | 890.47M |
| Vanda Pharmaceuticals Inc | -112.08M |
| ADMA Biologics Inc | 1.494B |
| Finch Therapeutics Group Inc | -21.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.71M |
| Revenue (Quarterly) | 77.97M |
| Total Expenses (Quarterly) | 120.26M |
| EPS Diluted (Quarterly) | -0.54 |
| Gross Profit Margin (Quarterly) | 98.95% |
| Profit Margin (Quarterly) | -41.95% |
| Earnings Yield | -70.21% |
| Normalized Earnings Yield | -65.89 |